Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.62) per share. This is a 40.91 percent decrease over losses of $(0.44) per share from the same period last year.
Petros Pharmaceuticals Partners With Blockbuster Cholesterol Drug Crestor’s OTC Switch Technology Provider
Idea Evolver is the only provider to successfully complete Actual Use Trial for FDA review for Rx-to-OTC Switch ApprovalNEW YORK, NY / ACCESSWIRE / December 12, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a
